Investor Talk #4 - Vesalius Biocapital
Thu, Sep 17
|The HIVE by Kadans Science Partner
Vesalius Biocapital will share it's investment strategy and priorities for 2026, to PSCC Connect start-ups only
Time & Location
Sep 17, 2026, 5:30 PM – 7:00 PM
The HIVE by Kadans Science Partner, 125 rue Edouard Vaillant, 94800 Villejuif, France
About the event
Investors Talks is a new event series dedicated to PSCC Connect start-ups only : an unfiltered meeting giving entrepreneurs direct access to leading investors in life sciences.
For the third edition, we will welcome Jean-Christophe Renondin, Partner at Vesalius Biocapital who will introduce Kurma's strategy for 2026.
During this informal session, Jean-Christophe will give us a behind-the scenes perspective on how one of Europe's leading life sciences VC firms identifies and supports the next generation of breakthrough medtech and biotech companies.
The discussion will cover:
Vesalius Biocapital's investment priorities and outlook for 2026–2027;
How leading European VCs evaluate and selects emerging biotechs;
What makes a company investable in today’s competitive landscape;
Common pitfalls startups encounter when approaching VCs
From how VCs truly assess opportunities to the type of relationships they seek to build, participants will gain practical, no-filter insights to better navigate their fundraising journey.